One gene to rule them all - clinical perspectives of a potent suppressor of cytokine signaling - SOCS1.

Front Immunol

Department of Infectious Diseases, Medical Microbiology and Hygiene, Medical Faculty, University Heidelberg, Heidelberg, Germany.

Published: May 2024

The discovery of Suppressor of Cytokine Signaling 1 (SOCS1) in 1997 marked a significant milestone in understanding the regulation of Janus kinase/Signal transducer and activator of transcription (JAK/STAT) signaling pathways. Subsequent research deciphered its cellular functions, and recent insights into SOCS1 deficiencies in humans underscored its critical role in immune regulation. In humans, SOCS-haploinsufficiency (SOCS1-HI) presents a diverse clinical spectrum, encompassing autoimmune diseases, infection susceptibility, and cancer. Variability in disease manifestation, even within families sharing the same genetic variant, raises questions about clinical penetrance and the need for individualized treatments. Current therapeutic strategies include JAK inhibition, with promising results in controlling inflammation in SOCS1-HI patients. Hematopoietic stem cell transplantation and gene therapy emerge as promising avenues for curative treatments. The evolving landscape of SOCS1 research, emphasizes the need for a nuanced understanding of genetic variants and their functional consequences.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11070515PMC
http://dx.doi.org/10.3389/fimmu.2024.1385190DOI Listing

Publication Analysis

Top Keywords

suppressor cytokine
8
cytokine signaling
8
signaling socs1
8
gene rule
4
rule clinical
4
clinical perspectives
4
perspectives potent
4
potent suppressor
4
socs1
4
socs1 discovery
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!